# Neurocrine Biosciences Inc. (NBIX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $155.64, market value $15.8 billion.

## Valuation
- **P/E (trailing): 22.8×** (5-yr avg 58.9×, 3-yr avg 41.7×). Neurocrine Biosciences Inc. trades at 22.8× trailing earnings, well below its own five-year average of 58.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.31**. A PEG of 0.31 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.7×**. Each dollar of revenue is priced at 4.7×.
- **Price / book: 4.3×**. The shares trade at 4.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 5.5%** (5-yr avg 3.5%). Free cash flow equals 5.5% of the market value, above its five-year average of 3.5%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 4.4%**. The inverse of the P/E: 4.4% of the price is earned each year.

## Profitability
- **Operating margin: 23.6%**. 23.6% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 16.7%**. 16.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 14.7%**. 14.7% on shareholders' equity is solid.
- **Return on assets: 15.2%**. Each dollar of assets produces 15.2% of profit.

## Growth
- **Revenue growth (1 yr): 21.4%** (3-yr 24.3%/yr, 5-yr 22.3%/yr). Revenue grew 21.4% over the last year, against 22.3% a year compounded over five years.
- **EPS growth (1 yr): 41.9%** (3-yr 44.1%/yr, 5-yr 2.3%/yr). Earnings per share rose 41.9%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 32.4%/yr**. Free cash flow has compounded at 32.4% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Current ratio: 3.39** (quick 3.39). Current assets cover the next year's liabilities 3.39 times.
- **Altman Z-score: 9.39**. A Z-score of 9.39 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Neurocrine Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (27 analysts). 27 analysts cover Neurocrine Biosciences Inc.; the consensus is strong_buy, with an average price target of $211.72 (+36% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 10.9%** (YTD 9.7%, 3-mo -5.0%). The shares are up 10.9% over twelve months including dividends.
- **From 52-week high: -16.4%** (27.4% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 0.66** (volatility 33%). Beta of 0.66 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NBIX · Page: https://foliofundamentals.com/stocks/nbix

Not investment advice.